Global Drug Abuse Testing
Global Drug Abuse Testing

Drug Abuse Testing Comprehensive Study by Type (Analyzers, Rapid Testing Devices, Consumables, Laboratory Services), Sample (Urine, Oral Fluid, Breath, Hair, Others), End User (Workplaces & Schools, Criminal Justice Systems & Law Enforcement Agencies, Research Laboratories, Hospitals) Players and Region - Global Market Outlook to 2026

Drug Abuse Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 242 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Drug Abuse Testing Market Scope
Drug abuse is the deliberate consumption of an illegal drug or overindulgence of a prescribed psychoactive or performance-enhancing drug for non-therapeutic, non-medicinal use/effects. Addicted individuals have uncontrollable, irresistible, and compulsive desire and persistence in its use despite negative consequences. Drug abuse test is a non-invasive technical analysis of biological samples. There are a number of ways this can be done, including pre-employment testing, random testing, reasonable suspicion/cause testing, post-accident testing, return to duty testing and follow-up testing. This usually involves collecting urine samples to test for drugs such as marijuana, cocaine, amphetamines, PCP, and opiates.

The Drug Abuse Testing market study is segmented by Type (Analyzers, Rapid Testing Devices, Consumables and Laboratory Services) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Quest Diagnostics (United States), Laboratory Corporation of America Holdings (LabCorp) (United States), Abbott Laboratories (United States), Randox laboratories (United Kingdom), Bio-Rad Laboratories, Inc.(United States), Sonic Healthcare (Australia), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific, Inc. (United States), Shimadzu Corporation, Danaher Corporation, Siemens AG, Merck KGaA, Drägerwerk AG & Co. KGaA, bioMérieux SA and Waters Corporation are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Drug Abuse Testing market by Type, Application and Region.

On the basis of geography, the market of Drug Abuse Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Feb. 2019, Quest Diagnostics and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.
In Jul 2019, Shimadzu Corporation has released version 2 of its GC/MS Forensic Toxicological Database for gas chromatograph mass spectrometers (GC/MS). Since 2010, Shimadzu has been marketing a database for the simultaneous screening of forensic chemicals such as drugs and/or toxic substances to police crime laboratories, university forensic departments, and emersency care facilities


Market Trend
  • Development of Novel Drug Testing Equipment

Market Drivers
  • Increasing Number of People who Consume Alcohol and Illicit Drugs such as Marijuana, Cocaine, and Others
  • Growing Drug related Mortality

Opportunities
  • Stringent Government Regulations Mandating Drug Screening
  • Technological Advancements in Drug Screening/Testing Devices

Restraints
  • Consideration of Drug Testing as a Breach of Privacy Rights in Certain Countries

Challenges
  • Lack of Awareness related Drug Abuse Testing


Key Target Audience
Drug Abuse Testing Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Analyzers
  • Rapid Testing Devices
  • Consumables
  • Laboratory Services
By Sample
  • Urine
  • Oral Fluid
  • Breath
  • Hair
  • Others

By End User
  • Workplaces & Schools
  • Criminal Justice Systems & Law Enforcement Agencies
  • Research Laboratories
  • Hospitals

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of People who Consume Alcohol and Illicit Drugs such as Marijuana, Cocaine, and Others
      • 3.2.2. Growing Drug related Mortality
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness related Drug Abuse Testing
    • 3.4. Market Trends
      • 3.4.1. Development of Novel Drug Testing Equipment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug Abuse Testing, by Type, Sample, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Drug Abuse Testing (Value)
      • 5.2.1. Global Drug Abuse Testing by: Type (Value)
        • 5.2.1.1. Analyzers
        • 5.2.1.2. Rapid Testing Devices
        • 5.2.1.3. Consumables
        • 5.2.1.4. Laboratory Services
      • 5.2.2. Global Drug Abuse Testing by: Sample (Value)
        • 5.2.2.1. Urine
        • 5.2.2.2. Oral Fluid
        • 5.2.2.3. Breath
        • 5.2.2.4. Hair
        • 5.2.2.5. Others
      • 5.2.3. Global Drug Abuse Testing by: End User (Value)
        • 5.2.3.1. Workplaces & Schools
        • 5.2.3.2. Criminal Justice Systems & Law Enforcement Agencies
        • 5.2.3.3. Research Laboratories
        • 5.2.3.4. Hospitals
      • 5.2.4. Global Drug Abuse Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Drug Abuse Testing (Price)
      • 5.3.1. Global Drug Abuse Testing by: Type (Price)
  • 6. Drug Abuse Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Quest Diagnostics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Laboratory Corporation of America Holdings (LabCorp) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Randox laboratories (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bio-Rad Laboratories, Inc.(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sonic Healthcare (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shimadzu Corporation
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Danaher Corporation
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Siemens AG
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Merck KGaA
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Drägerwerk AG & Co. KGaA
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. BioMérieux SA
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Waters Corporation
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Drug Abuse Testing Sale, by Type, Sample, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Drug Abuse Testing (Value)
      • 7.2.1. Global Drug Abuse Testing by: Type (Value)
        • 7.2.1.1. Analyzers
        • 7.2.1.2. Rapid Testing Devices
        • 7.2.1.3. Consumables
        • 7.2.1.4. Laboratory Services
      • 7.2.2. Global Drug Abuse Testing by: Sample (Value)
        • 7.2.2.1. Urine
        • 7.2.2.2. Oral Fluid
        • 7.2.2.3. Breath
        • 7.2.2.4. Hair
        • 7.2.2.5. Others
      • 7.2.3. Global Drug Abuse Testing by: End User (Value)
        • 7.2.3.1. Workplaces & Schools
        • 7.2.3.2. Criminal Justice Systems & Law Enforcement Agencies
        • 7.2.3.3. Research Laboratories
        • 7.2.3.4. Hospitals
      • 7.2.4. Global Drug Abuse Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Drug Abuse Testing (Price)
      • 7.3.1. Global Drug Abuse Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug Abuse Testing: by Type(USD Million)
  • Table 2. Drug Abuse Testing Analyzers , by Region USD Million (2015-2020)
  • Table 3. Drug Abuse Testing Rapid Testing Devices , by Region USD Million (2015-2020)
  • Table 4. Drug Abuse Testing Consumables , by Region USD Million (2015-2020)
  • Table 5. Drug Abuse Testing Laboratory Services , by Region USD Million (2015-2020)
  • Table 6. Drug Abuse Testing: by Sample(USD Million)
  • Table 7. Drug Abuse Testing Urine , by Region USD Million (2015-2020)
  • Table 8. Drug Abuse Testing Oral Fluid , by Region USD Million (2015-2020)
  • Table 9. Drug Abuse Testing Breath , by Region USD Million (2015-2020)
  • Table 10. Drug Abuse Testing Hair , by Region USD Million (2015-2020)
  • Table 11. Drug Abuse Testing Others , by Region USD Million (2015-2020)
  • Table 12. Drug Abuse Testing: by End User(USD Million)
  • Table 13. Drug Abuse Testing Workplaces & Schools , by Region USD Million (2015-2020)
  • Table 14. Drug Abuse Testing Criminal Justice Systems & Law Enforcement Agencies , by Region USD Million (2015-2020)
  • Table 15. Drug Abuse Testing Research Laboratories , by Region USD Million (2015-2020)
  • Table 16. Drug Abuse Testing Hospitals , by Region USD Million (2015-2020)
  • Table 17. South America Drug Abuse Testing, by Country USD Million (2015-2020)
  • Table 18. South America Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 19. South America Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 20. South America Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 21. Brazil Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 22. Brazil Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 23. Brazil Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 24. Argentina Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 25. Argentina Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 26. Argentina Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 27. Rest of South America Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 29. Rest of South America Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 30. Asia Pacific Drug Abuse Testing, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 33. Asia Pacific Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 34. China Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 35. China Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 36. China Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 37. Japan Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 38. Japan Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 39. Japan Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 40. India Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 41. India Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 42. India Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 43. South Korea Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 44. South Korea Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 45. South Korea Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 46. Taiwan Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 47. Taiwan Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 48. Taiwan Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 49. Australia Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 50. Australia Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 51. Australia Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 55. Europe Drug Abuse Testing, by Country USD Million (2015-2020)
  • Table 56. Europe Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 57. Europe Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 58. Europe Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 59. Germany Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 60. Germany Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 61. Germany Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 62. France Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 63. France Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 64. France Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 65. Italy Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 66. Italy Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 67. Italy Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 68. United Kingdom Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 70. United Kingdom Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 71. Netherlands Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 72. Netherlands Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 73. Netherlands Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 74. Rest of Europe Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 76. Rest of Europe Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 77. MEA Drug Abuse Testing, by Country USD Million (2015-2020)
  • Table 78. MEA Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 79. MEA Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 80. MEA Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 81. Middle East Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 82. Middle East Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 83. Middle East Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 84. Africa Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 85. Africa Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 86. Africa Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 87. North America Drug Abuse Testing, by Country USD Million (2015-2020)
  • Table 88. North America Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 89. North America Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 90. North America Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 91. United States Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 92. United States Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 93. United States Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 94. Canada Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 95. Canada Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 96. Canada Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 97. Mexico Drug Abuse Testing, by Type USD Million (2015-2020)
  • Table 98. Mexico Drug Abuse Testing, by Sample USD Million (2015-2020)
  • Table 99. Mexico Drug Abuse Testing, by End User USD Million (2015-2020)
  • Table 100. Drug Abuse Testing: by Type(USD/Units)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Drug Abuse Testing: by Type(USD Million)
  • Table 117. Drug Abuse Testing Analyzers , by Region USD Million (2021-2026)
  • Table 118. Drug Abuse Testing Rapid Testing Devices , by Region USD Million (2021-2026)
  • Table 119. Drug Abuse Testing Consumables , by Region USD Million (2021-2026)
  • Table 120. Drug Abuse Testing Laboratory Services , by Region USD Million (2021-2026)
  • Table 121. Drug Abuse Testing: by Sample(USD Million)
  • Table 122. Drug Abuse Testing Urine , by Region USD Million (2021-2026)
  • Table 123. Drug Abuse Testing Oral Fluid , by Region USD Million (2021-2026)
  • Table 124. Drug Abuse Testing Breath , by Region USD Million (2021-2026)
  • Table 125. Drug Abuse Testing Hair , by Region USD Million (2021-2026)
  • Table 126. Drug Abuse Testing Others , by Region USD Million (2021-2026)
  • Table 127. Drug Abuse Testing: by End User(USD Million)
  • Table 128. Drug Abuse Testing Workplaces & Schools , by Region USD Million (2021-2026)
  • Table 129. Drug Abuse Testing Criminal Justice Systems & Law Enforcement Agencies , by Region USD Million (2021-2026)
  • Table 130. Drug Abuse Testing Research Laboratories , by Region USD Million (2021-2026)
  • Table 131. Drug Abuse Testing Hospitals , by Region USD Million (2021-2026)
  • Table 132. South America Drug Abuse Testing, by Country USD Million (2021-2026)
  • Table 133. South America Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 134. South America Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 135. South America Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 136. Brazil Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 137. Brazil Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 138. Brazil Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 139. Argentina Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 140. Argentina Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 141. Argentina Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 142. Rest of South America Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 143. Rest of South America Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 144. Rest of South America Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 145. Asia Pacific Drug Abuse Testing, by Country USD Million (2021-2026)
  • Table 146. Asia Pacific Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 147. Asia Pacific Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 148. Asia Pacific Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 149. China Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 150. China Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 151. China Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 152. Japan Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 153. Japan Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 154. Japan Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 155. India Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 156. India Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 157. India Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 158. South Korea Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 159. South Korea Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 160. South Korea Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 161. Taiwan Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 162. Taiwan Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 163. Taiwan Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 164. Australia Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 165. Australia Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 166. Australia Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 168. Rest of Asia-Pacific Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 169. Rest of Asia-Pacific Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 170. Europe Drug Abuse Testing, by Country USD Million (2021-2026)
  • Table 171. Europe Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 172. Europe Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 173. Europe Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 174. Germany Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 175. Germany Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 176. Germany Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 177. France Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 178. France Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 179. France Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 180. Italy Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 181. Italy Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 182. Italy Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 183. United Kingdom Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 184. United Kingdom Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 185. United Kingdom Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 186. Netherlands Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 187. Netherlands Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 188. Netherlands Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 189. Rest of Europe Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 190. Rest of Europe Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 191. Rest of Europe Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 192. MEA Drug Abuse Testing, by Country USD Million (2021-2026)
  • Table 193. MEA Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 194. MEA Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 195. MEA Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 196. Middle East Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 197. Middle East Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 198. Middle East Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 199. Africa Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 200. Africa Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 201. Africa Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 202. North America Drug Abuse Testing, by Country USD Million (2021-2026)
  • Table 203. North America Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 204. North America Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 205. North America Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 206. United States Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 207. United States Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 208. United States Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 209. Canada Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 210. Canada Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 211. Canada Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 212. Mexico Drug Abuse Testing, by Type USD Million (2021-2026)
  • Table 213. Mexico Drug Abuse Testing, by Sample USD Million (2021-2026)
  • Table 214. Mexico Drug Abuse Testing, by End User USD Million (2021-2026)
  • Table 215. Drug Abuse Testing: by Type(USD/Units)
  • Table 216. Research Programs/Design for This Report
  • Table 217. Key Data Information from Secondary Sources
  • Table 218. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug Abuse Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Drug Abuse Testing: by Sample USD Million (2015-2020)
  • Figure 6. Global Drug Abuse Testing: by End User USD Million (2015-2020)
  • Figure 7. South America Drug Abuse Testing Share (%), by Country
  • Figure 8. Asia Pacific Drug Abuse Testing Share (%), by Country
  • Figure 9. Europe Drug Abuse Testing Share (%), by Country
  • Figure 10. MEA Drug Abuse Testing Share (%), by Country
  • Figure 11. North America Drug Abuse Testing Share (%), by Country
  • Figure 12. Global Drug Abuse Testing: by Type USD/Units (2015-2020)
  • Figure 13. Global Drug Abuse Testing share by Players 2020 (%)
  • Figure 14. Global Drug Abuse Testing share by Players (Top 3) 2020(%)
  • Figure 15. Global Drug Abuse Testing share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 18. Quest Diagnostics (United States) Revenue: by Geography 2020
  • Figure 19. Laboratory Corporation of America Holdings (LabCorp) (United States) Revenue, Net Income and Gross profit
  • Figure 20. Laboratory Corporation of America Holdings (LabCorp) (United States) Revenue: by Geography 2020
  • Figure 21. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 23. Randox laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Randox laboratories (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Bio-Rad Laboratories, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 26. Bio-Rad Laboratories, Inc.(United States) Revenue: by Geography 2020
  • Figure 27. Sonic Healthcare (Australia) Revenue, Net Income and Gross profit
  • Figure 28. Sonic Healthcare (Australia) Revenue: by Geography 2020
  • Figure 29. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 31. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Shimadzu Corporation Revenue, Net Income and Gross profit
  • Figure 34. Shimadzu Corporation Revenue: by Geography 2020
  • Figure 35. Danaher Corporation Revenue, Net Income and Gross profit
  • Figure 36. Danaher Corporation Revenue: by Geography 2020
  • Figure 37. Siemens AG Revenue, Net Income and Gross profit
  • Figure 38. Siemens AG Revenue: by Geography 2020
  • Figure 39. Merck KGaA Revenue, Net Income and Gross profit
  • Figure 40. Merck KGaA Revenue: by Geography 2020
  • Figure 41. Drägerwerk AG & Co. KGaA Revenue, Net Income and Gross profit
  • Figure 42. Drägerwerk AG & Co. KGaA Revenue: by Geography 2020
  • Figure 43. BioMérieux SA Revenue, Net Income and Gross profit
  • Figure 44. BioMérieux SA Revenue: by Geography 2020
  • Figure 45. Waters Corporation Revenue, Net Income and Gross profit
  • Figure 46. Waters Corporation Revenue: by Geography 2020
  • Figure 47. Global Drug Abuse Testing: by Type USD Million (2021-2026)
  • Figure 48. Global Drug Abuse Testing: by Sample USD Million (2021-2026)
  • Figure 49. Global Drug Abuse Testing: by End User USD Million (2021-2026)
  • Figure 50. South America Drug Abuse Testing Share (%), by Country
  • Figure 51. Asia Pacific Drug Abuse Testing Share (%), by Country
  • Figure 52. Europe Drug Abuse Testing Share (%), by Country
  • Figure 53. MEA Drug Abuse Testing Share (%), by Country
  • Figure 54. North America Drug Abuse Testing Share (%), by Country
  • Figure 55. Global Drug Abuse Testing: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Quest Diagnostics (United States)
  • Laboratory Corporation of America Holdings (LabCorp) (United States)
  • Abbott Laboratories (United States)
  • Randox laboratories (United Kingdom)
  • Bio-Rad Laboratories, Inc.(United States)
  • Sonic Healthcare (Australia)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Thermo Fisher Scientific, Inc. (United States)
  • Shimadzu Corporation
  • Danaher Corporation
  • Siemens AG
  • Merck KGaA
  • Drägerwerk AG & Co. KGaA
  • bioMérieux SA
  • Waters Corporation
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation